Radioembolization for Hepatocellular Carcinoma
- 1 August 2011
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in American Journal of Clinical Oncology
- Vol. 34 (4), 422-431
- https://doi.org/10.1097/coc.0b013e3181df0a50
Abstract
Treatment decisions for hepatocellular carcinoma involve the evaluation of multiple factors including tumor size, location, and morphology; comorbidity and/or extrahepatic disease; health status; patient preferences; and the treating physician's expertise and skill. For patients who are not candidates for transplant or resection, and for whom other therapies (radiofrequency ablation, systemic chemotherapies, transarterial embolization or chemoembolization), may have limited efficacy, an urgent need for bridging procedures, to enable surgery or ablation, or meet transplantation criteria, has led to investigations with radioembolization. A number of recent reports have supported the effectiveness of Yttrium-90 ((90)Y) labeled microspheres to treat intermediate and advanced disease in patients with good overall functional status and liver reserve; patients with portal vein involvement and in a limited role to treat unresectable early-stage disease. This review addresses response rates and survival benefit following radioembolization in different patient populations, in centers throughout Europe, North America, and Asia, and across the spectrum of patients presenting with various prognostic factors. By using stringent selection criteria and conservative models for calculating radiation dosage, radioembolization can be performed safely even in cirrhotic patients, without postembolization syndrome or radiation-induced liver disease, and even with multiple treatments to whole or part of the liver.Keywords
This publication has 45 references indexed in Scilit:
- Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and managementWorld Journal of Gastroenterology, 2009
- Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II)Cancer Causes & Control, 2008
- Outcomes of Neoadjuvant Transarterial Chemoembolization to Downstage Hepatocellular Carcinoma Before Liver TransplantationAnnals of Surgery, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402)European Journal of Cancer, 2008
- Evolution of systemic therapy of advanced hepatocellular carcinomaWorld Journal of Gastroenterology, 2008
- Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicityOncogene, 2006
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trialJournal of Hepatology, 1998
- A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinomaCancer, 1992